← Shanghai Haoyuan Chemexpress Co. Ltd. A overview

Shanghai Haoyuan Chemexpress Co. Ltd. A vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shanghai Haoyuan Chemexpress Co. Ltd. A (688131.CG)

Q3 202629 Jul – 23 Sep 2026

▲4

Haoyuan's FDA clearance, profit growth and China drug policy lift shares

FDA zero-deficiency inspection opens U.S. market Its Qidong subsidiary passed a U.S. FDA pre-approval inspection with zero deficiencies — the first time its finished-dose plant cleared U.S. scrutiny. That opens the door to selling formulations in America, a new revenue source and a credibility boost for the whole company.
A concrete regulatory milestone that expands the addressable market and supports future earnings.
First-half profit up 12.8%, revenue up 25.7% Revenue rose 25.71% to 1.648 billion yuan and net profit rose 12.81% to 171 million yuan. Life-science reagents grew fastest at 34%, showing the core research-supply business is still expanding even as margins slipped slightly.
The half-year results are the clearest evidence of the company's underlying earnings trend.
Cash dividend signals confidence and returns capital The company will pay 0.9 yuan per 10 shares, about 19.2 million yuan, roughly 11% of first-half profit. A payout alongside growth tells investors management is confident about cash flow and is willing to share it.
Dividend policy is a direct signal of financial health and shareholder returns.
15th Five-Year Plan backs biomedicine and drug exports Ten ministries set biomedicine as a pillar industry with 2030 revenue targets and 20%+ innovative-drug growth, while Chinese drug out-licensing deals topped $120 billion, up 36%. Better approval and payment policy plus recovering CRO demand lift the whole sector Haoyuan supplies.
Sector-wide policy and demand tailwinds are the main external force behind the stock's re-rating.

August 202629 Jul – 23 Sep 2026

▲4

Haoyuan's FDA clearance, profit growth and China drug policy lift shares

FDA zero-deficiency inspection opens U.S. market Its Qidong subsidiary passed a U.S. FDA pre-approval inspection with zero deficiencies — the first time its finished-dose plant cleared U.S. scrutiny. That opens the door to selling formulations in America, a new revenue source and a credibility boost for the whole company.
A concrete regulatory milestone that expands the addressable market and supports future earnings.
First-half profit up 12.8%, revenue up 25.7% Revenue rose 25.71% to 1.648 billion yuan and net profit rose 12.81% to 171 million yuan. Life-science reagents grew fastest at 34%, showing the core research-supply business is still expanding even as margins slipped slightly.
The half-year results are the clearest evidence of the company's underlying earnings trend.
Cash dividend signals confidence and returns capital The company will pay 0.9 yuan per 10 shares, about 19.2 million yuan, roughly 11% of first-half profit. A payout alongside growth tells investors management is confident about cash flow and is willing to share it.
Dividend policy is a direct signal of financial health and shareholder returns.
15th Five-Year Plan backs biomedicine and drug exports Ten ministries set biomedicine as a pillar industry with 2030 revenue targets and 20%+ innovative-drug growth, while Chinese drug out-licensing deals topped $120 billion, up 36%. Better approval and payment policy plus recovering CRO demand lift the whole sector Haoyuan supplies.
Sector-wide policy and demand tailwinds are the main external force behind the stock's re-rating.

Latest29 Jul – 23 Sep 2026

▲4

Haoyuan's FDA clearance, profit growth and China drug policy lift shares

FDA zero-deficiency inspection opens U.S. market Its Qidong subsidiary passed a U.S. FDA pre-approval inspection with zero deficiencies — the first time its finished-dose plant cleared U.S. scrutiny. That opens the door to selling formulations in America, a new revenue source and a credibility boost for the whole company.
A concrete regulatory milestone that expands the addressable market and supports future earnings.
First-half profit up 12.8%, revenue up 25.7% Revenue rose 25.71% to 1.648 billion yuan and net profit rose 12.81% to 171 million yuan. Life-science reagents grew fastest at 34%, showing the core research-supply business is still expanding even as margins slipped slightly.
The half-year results are the clearest evidence of the company's underlying earnings trend.
Cash dividend signals confidence and returns capital The company will pay 0.9 yuan per 10 shares, about 19.2 million yuan, roughly 11% of first-half profit. A payout alongside growth tells investors management is confident about cash flow and is willing to share it.
Dividend policy is a direct signal of financial health and shareholder returns.
15th Five-Year Plan backs biomedicine and drug exports Ten ministries set biomedicine as a pillar industry with 2030 revenue targets and 20%+ innovative-drug growth, while Chinese drug out-licensing deals topped $120 billion, up 36%. Better approval and payment policy plus recovering CRO demand lift the whole sector Haoyuan supplies.
Sector-wide policy and demand tailwinds are the main external force behind the stock's re-rating.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.